EMA makes new rec­om­men­da­tions for Im­bru­vi­ca, med­i­cines with ter­li­pressin over res­pi­ra­to­ry and car­dio­vas­cu­lar risks

The EMA is hand­ing out a new rec­om­men­da­tion sur­round­ing J&J and Ab­b­Vie’s can­cer drug Im­bru­vi­ca and some med­i­cines con­tain­ing ter­li­pressin.

On Fri­day, the EMA’s safe­ty com­mit­tee (PRAC) stat­ed that it has tak­en new mea­sures to re­duce the risk of res­pi­ra­to­ry fail­ure and sep­sis when med­i­cines con­tain­ing ter­li­pressin that are used to treat peo­ple with he­pa­tore­nal syn­drome (HRS-1), par­tic­u­lar­ly for pa­tients with ad­vanced acute-on-chron­ic liv­er dis­ease or ad­vanced kid­ney fail­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.